英文論文
- 2024
- 2023
- 2022
- 2021
- 2020
- 2019
- 2018
- 2017
- 2016
- 2015
- 2014
- 2013
- 2012
- 2011
- 2010
- 2009
- 2008
- 2007
- 2006
- 2005
- 2004
Katagiri A, Fu KI, Sano Y, Ikematsu H, Horimatsu T, Kaneko K, Muto M, Yoshida S.
Narrow band imaging with magnifying colonoscopy as a diagnostic tool for predicting the histology of early colorectal neoplasia.
Alim Pharm & Therap 27(12):1269-74,2008
Sangai T, Fujimoto H, Miyamoto S, Maeda H, Nakamura M, Ishii G, Nagai K, Nagashima T, Miyazaki M, Ochiai A.
Roles of osteoclasts and bone-derived IGFs in the survival and growth of human breast cancer cells in human adult bone implanted into nonobese diabetic/severe combined immunodeficient mice.
Clin Exp Metastasis. 2008;25(4):401-10.
Yamada A, Sasaki H, Aoyagi K, Sano M, Fujii S, Daiko H, Nishimura M, Yoshida T, Chiba T, Ochiai A.
Expression of cytokeratin 7 predicts survival in stage I/IIA/IIB squamous cell carcinoma of the esophagus.
Oncol Rep. 2008;20(5):1021-7.
Matsubara J, Nishina T, Yamada Y, Moriwaki T, Shimoda T, Kajiwara T, Nakajima TE, Kato K, Hamaguchi T, Shimada Y, Okayama Y, Oka T, Shirao K:
Impacts of excision repair cross-complementing gene 1 (ERCC1), dihydropyrimidine dehydrogenase, and epidermal growth factor receptor on the outcomes of patients with advanced gastric cancer.
Br J Cancer 2008; 98: 832-839.
Matsubara J, Okusaka T, Morizane C, Ikeda M, Ueno H:
Ultrasound-guided percutaneous pancreatic tumor biopsy in pancreatic cancer: a comparison with metastatic liver tumor biopsy, including sensitivity, specificity, and complications.
J Gastroenterol 2008; 43: 225-232.
Matsubara J, Yamada Y, Hirashima Y, Takahari D, Okita NT, Kato K, Hamaguchi T, Shirao K, Shimada Y, Shimoda T:
Impact of insulin-like growth factor type 1 receptor (IGF-1R), epidermal growth factor receptor (EGFR), and HER2 expressions on outcomes of patients with gastric cancer.
Clin Cancer Res 2008; 14: 3022-3029.
Matsubara J, Yamada Y, Nakajima TE, Kato K, Hamaguchi T, Shirao K, Shimada Y, Shimoda T:
Clinical significance of insulin-like growth factor type 1 receptor and epidermal growth factor receptor in patients with advanced gastric cancer.
Oncology 2008; 74: 76-83.
Matsubara J, Shimada Y, Takashima A, Takahari D, Hirashima Y, Okita NT, Nakajima TE, Kato K, Hamaguchi T, Yamada Y, Shirao K:
A phase I study of bolus 5-fluorouracil and leucovorin combined with weekly paclitaxel (FLTAX) as first-line therapy for advanced gastric cancer.
Jpn J Clin Oncol 2008; 38: 540-546.
Matsumoto S, Nishimura T, Kanai M, Mori Y, Nagayama S, Kawamura J, Nomura A, Miyamoto S, Kitano T, Ishiguro H, Yanagihara K, Teramukai S, Sakai Y, Chiba T, Fukushima M.
Safety and efficacy of modified FOLFOX6 for treatment of metastatic or locally advanced colorectal cancer. A single-institution outcome study.
Chemotherapy 2008;54:395-403.
Yamada A, Sasaki H, Aoyagi K, Sano M, Fujii S, Daiko H, Nishimura M, Yoshida T, Chiba T, Ochiai A.
Expression of cytokeratin 7 predicts survival in stage I/IIA/IIB squamous cell carcinoma of the esophagus.
Oncol Rep. 2008;20(5):1021-7.